Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5657248 | Clinical Gastroenterology and Hepatology | 2017 | 22 Pages |
Abstract
Viral eradication was associated with clinical improvement in most patients with CV. Markers of immune activation, including circulating cryoglobulins, persisted in 52% of patients with CV or ACC, despite a sustained viral response 12 weeks after therapy. A longer follow-up period after viral eradication might be necessary to ensure a normal immune response.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
MartÃn Bonacci, Sabela Lens, MarÃa-Carlota Londoño, Zoe Mariño, Maria C. Cid, Manuel Ramos-Casals, Jose MarÃa Sánchez-Tapias, Xavier Forns, José Hernández-RodrÃguez,